Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12319238 | 0.81 | KIT (0.39) | KITBRD4ACHEHDAC6NLRP3 | |
| SCHEMBL18007714 | 0.81 | NLRP3 (0.44) | ALDH1A1HSD17B10TDP1ACHENLRP3 | |
| SCHEMBL15193589 | 0.81 | KIT (0.36) | KITBRD4ACHENLRP3 | |
| SCHEMBL22021175 | 0.81 | KIT (0.39) | KITBRD4TDP1ACHE | |
| SCHEMBL22531632 | 0.75 | ACHE (0.36) | ACHE | |
| SCHEMBL22531631 | 0.75 | ACHE (0.36) | ACHE | |
| SCHEMBL22021182 | 0.74 | BRD4 (0.34) | KITBRD4 | |
| SCHEMBL22531744 | 0.74 | ACHE (0.37) | ALDH1A1HSD17B10TDP1ACHENLRP3 | |
| SCHEMBL22531742 | 0.74 | ACHE (0.37) | ALDH1A1HSD17B10TDP1ACHENLRP3 | |
| SCHEMBL23850653 | 0.73 | ACHE (0.36) | ALDH1A1HSD17B10TDP1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400564-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | SYNDAX PHARMACEUTICALS, INC. | 2024-12-05 | — | — | US | disclosed |
| CN-117956992-A | MENIN-MLL interaction inhibitors | 赛达克斯制药股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-4337203-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | Syndax Pharmaceuticals, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11919901-B2 | Inhibitors of the menin-MLL interaction | SYNDAX PHARMACEUTICALS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230151016-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
| US-11566030-B2 | Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20230021684-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | SYNDAX PHARMACEUTICALS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230021684-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | SYNDAX PHARMACEUTICALS, INC. | 2023-01-26 | — | — | US | disclosed |
| WO-2022241265-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | SYNDAX PHARMACEUTICALS, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| EP-2396296-A1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott GmbH & Co. KG (DE) | 2011-12-21 | — | — | EP | disclosed |
| EP-2364979-A1 | Pyrrole compounds | Takeda Pharmaceutical Company Limited (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20100273739-A1 | Aminotetraline Derivatives, Pharmaceutical Composition, Containing Them, and Their Use in Therapy | ABBVIE INC. | 2010-10-28 | — | — | US | disclosed |
| WO-2010092180-A1 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT GMBH & CO. KG (DE) | 2010-08-19 | — | — | WO | disclosed |
| EP-2114917-A2 | PYRROLE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2009-11-11 | — | — | EP | disclosed |
| EP-2074118-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | AstraZeneca AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| WO-2009007748-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
| US-20080262042-A1 | 1-[5-(2-Fluoropyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or a salt thereof; acid secretion inhibitor; potassium-competitive acid blocker | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-23 | — | — | US | disclosed |
| WO-2008108380-A2 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262042-A1 | 1-[5-(2-Fluoropyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or a salt thereof; acid secretion inhibitor; potassium-competitive acid blocker | REN, HRH2, ATP4A | KIT 1874/4885BRD4 882/4885ALDH1A1 1650/4885 |
| US-11566030-B2 | Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators | PDK1, PDK2, PDK3 | KIT 1440/4885BRD4 3236/4885ALDH1A1 1703/4885 |
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | KIT 3641/4885BRD4 1115/4885ALDH1A1 1972/4885 |
| US-20090018134-A1 | Compounds - 945 | MTOR, PIK3CA, PIK3R5 | KIT 1110/4885BRD4 2299/4885ALDH1A1 2861/4885 |
| US-11919901-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | KIT 2318/4885BRD4 170/4885ALDH1A1 3965/4885 |
| US-20240400564-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | KIT 2332/4885BRD4 172/4885ALDH1A1 3933/4885 |
| US-20100273739-A1 | Aminotetraline Derivatives, Pharmaceutical Composition, Containing Them, and Their Use in Therapy | AADAT, GFPT1, BCAT1 | KIT 4193/4885BRD4 3129/4885ALDH1A1 1487/4885 |
| US-20230151016-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | PDK1, PDK2, PKM | KIT 1809/4885BRD4 3068/4885ALDH1A1 1784/4885 |
| US-20230021684-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | KIT 2332/4885BRD4 172/4885ALDH1A1 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.